The World Anti-Doping Agency (WADA) has issued a new list of prohibited substances for 2010 and a new International Standards for Therapeutic Use Exemption (TUE), which will come into effect on 1 January 2010.
List of prohibited substances 2010
Following questions from team doctors on this issue, the status of platelet-derived preparations (e.g. platelet-rich plasma, "blood spinning") has been clarified: such preparations are prohibited when administered by the intramuscular route, but all other routes of administration require only a declaration of use. Three stimulants – benfluorex, prenylamine and methylhexaneamine – have been added to the list of non-specified stimulants. Pseudoephedrine has been reintroduced to the 2010 prohibited list at a urinary threshold of 150 mcg/mL.
As of 1 January 2010, the therapeutic use of salbutamol and salmeterol does not require a TUE, but a declaration of use. Their use must be declared on the Declaration of Medication (D3) form by the player/doctor during a doping control. All other beta-2 agonists (including formoterol and terbutaline) are prohibited, so therefore still require TUE granted on the basis of the full medical report (see below). Application forms must be accompanied by a full medical file (relevant spirometry reports with values compliant with WADA requirements) as stipulated in documents 'Asthma TUE requirements' (amended accordingly).
Declaration of Use procedure
Inhaled salbutamol (maximum 1600 mcg / 24 hours), inhaled salmeterol and platelet-rich plasma (if administered locally) must be declared on the D3 Declaration of Medication form during a doping control. Failure to declare may lead to disciplinary action in the event of an adverse analytical finding (positive result). No changes were introduced in respect of glucocorticosteroids (GCS) administered by non-systemic routes.
©UEFA.com 1998-2013. All rights reserved.